CEO
Bloomsbury Genetic Therapies
Bloomsbury Genetic Therapies develops gene therapy treatments targeting rare neurological and metabolic diseases using adeno-associated virus (AAV) vectors and optimized vector constructs. The company aims to provide potentially curative options for patients with high unmet medical needs, leveraging proven technologies to advance its clinical-stage pipeline.
- Biotechnology
Updated 23 months ago
Funding
Raised to date
$6MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Problem
Many rare neurological and metabolic diseases lack effective treatments, leaving patients with limited or no therapeutic options. Traditional approaches often fail to address the underlying genetic causes of these conditions, resulting in symptomatic relief rather than curative outcomes.
Solution
Bloomsbury Genetic Therapies is a clinical-stage biotechnology company focused on developing potentially curative gene therapy treatments for rare neurological and metabolic diseases. The company leverages adeno-associated virus (AAV) vectors and optimized vector constructs to deliver functional genes to target cells, addressing the root cause of the disease. By utilizing clinically proven gene therapy technologies and novel routes of administration, Bloomsbury aims to provide first- or best-in-class therapies for patients with high unmet medical needs. Their approach is supported by partnerships with University College London (UCL) and leading contract development and manufacturing organizations (CDMOs).
Target Audience
The primary target audience includes patients suffering from rare neurological and metabolic diseases, as well as the healthcare providers who treat them.
Features
- Utilizes well-characterized AAV capsids for efficient gene delivery.
- Employs optimized vector constructs to enhance therapeutic gene expression.
- Focuses on rare neurological and metabolic diseases with clear and translatable biology.
- Programs have demonstrated compelling preclinical data.
- Developing novel routes of administration.